EHA 2015: Lenalidomide in relapsed or refractory mantle cell lymphoma - 101793

Spotlight
Video

EHA 2015: Lenalidomide in relapsed or refractory mantle cell lymphoma

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, presents the results of a subgroup analysis of the phase 2 SPRINT trial at the 20th Congress of the European Hematology Association (EHA). The results showed that lenalidomide, an immunomodulator, provided clinically significant improved activity irrespective of baseline demographics or disease characteristics when compared with investigator’s choice in patients with relapsed or refractory mantle cell lymphoma.

—————

The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve understanding and awareness of hematological malignancies.

Website: http://www.vjhemonc.com/...
Twitter: https://twitter.com/VJHemOn...
Facebook: https://www.facebook.com/vj...
LinkedIn: https://www.linkedin.com/co...
Shared By : VJHemOnc
Posted on : 07/10/15
Added : 4 years ago